Germany's aap Implantate Q3 revenue rises on US growth

Overview

• Germany medical device maker's Q3 revenue rose 2% yr/yr to EUR 3.3 mln

• Company's U.S. business grew 2% in local currency in Q3

• EBITDA for first nine months stayed above break-even, reflecting operational improvements

Outlook

• Company expects to further reduce cumulative revenue shortfall in Q4

• aap sees progress and additional growth in APAC in Q4

• Company began Q4 with highest monthly order intake of the year in U.S.

Result Drivers

• U.S. GROWTH - Co said U.S. business grew 2% in local currency in Q3, building on a strong prior-year quarter

• EMEA RECOVERY - Revenue in EMEA region rose 3% in Q3, with significant recovery in the Middle East and new product growth in Spain and Portugal

• LATAM STABILITY - LATAM revenue matched prior-year's strong Q3, as expanded product portfolio and new markets offset high one-time orders in 2025

Company press release:

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Aap Implantate AG is €1.68, about 19.1% above its November 9 closing price of €1.41

Reuters Recommended Reads

• Nov 9 - Orthofix Medical Q3 revenue misses; cuts full-year guidance due to weaker US Spine performance

• Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves

• Nov 9 - Oncology firm Delcath Systems' Q3 revenue beats on Hepzato growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)